+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases



Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases



Zhonghua Yi Xue Za Zhi 92(8): 524-527



To evaluate the efficacies of gefitinib plus radiotherapy in the treatment of brain metastases in non-small-cell lung carcinoma (NSCLC) patients. A retrospective analysis was conducted for 161 NSCLC patients with brain metastases treated in Xinqiao Hospital from January 2001 to January 2010. And 38 patients aged 38 - 77 years old received the combined regimen of gefitinib plus radiotherapy. It consisted of synchronically practicing general or stereotactic brain radiotherapy and an oral intake of gefitinib (250 mg, QD for at least 8 consecutive weeks). The efficacies and toxicity were evaluated at Week 12 after the initial treatment. A total of 123 patients aged 37 - 76 years old undergoing whole brain or stereotactic radiotherapy were used as control. χ(2) test between two groups was carried out to evaluate the objective response rate (ORR), disease control rate (DCR), brain metastasis related symptoms and III-IV degree of toxicity. Non-parametric rank tests were performed to compare the U.S. Eastern Cooperative Oncology Group (ECOG) performance status score between two groups. In the combination therapy group, the levels of ORR and DCR were significantly higher than those in the conventional treatment group (31.6%, 78.9% vs 15.4%, 60.2%). The differences were statistically significant (χ(2) = 4.859, P = 0.027 and χ(2) = 4.479, P = 0.034); significant difference existed in brain metastasis-related symptoms between two groups (χ(2) = 4.612, P = 0.037); the ECOG scores were evaluated in the combination therapy group. And they were as follows: 0 - 1 (n = 18), 2 (n = 11), 3 - 4 (n = 9) at pre-treatment vs 0 - 1 (n = 27), 2 (n = 6), 3 - 4 (n = 5) at post-treatment. The ECOG score significantly improved after treatment (Z = -2.012, P = 0.044). Regarding the III-IV degree of toxicity, the combination therapy group had 4 patients with acne-like rash and it was significantly higher than that in the conventional therapy group (n = 0) (P = 0.003). But no difference existed in the occurrence of fatigue, nausea, vomiting, diarrhea and myelosuppression. The combined regimen of gefitinib plus radiotherapy can improve the therapeutic efficacies of brain metastases and enhance the quality-of-life in NSCLC patients, side effects are tolerable.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053072407

Download citation: RISBibTeXText

PMID: 22490154


Related references

Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. Journal of Clinical Neuroscience 21(4): 591-595, 2014

Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports. Bmc Research Notes 9: 2, 2016

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. Biomed Research International 2016: 5807346, 2016

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). European Journal of Cancer 48(3): 377-384, 2012

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide A randomised phase II trial of the Swiss Group for Clinical Ca. 2011

Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer. Cell Biochemistry and Biophysics 71(2): 1261-1265, 2015

Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget 6(10): 8366-8376, 2015

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Annals of Oncology 15(7): 1042-1047, 2004

Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pacific Journal of Cancer Prevention 13(3): 909-914, 2012

Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clinical Lung Cancer 6(2): 123-128, 2004

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46(2): 255-261, 2004

Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer. Journal of Neurosurgery 117 Suppl: 49-56, 2012

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47(1): 129-138, 2005

Effect of gefitinib on brain metastases from non-small cell lung cancer. Neurologia Medico-Chirurgica 46(10): 504-507, 2006

Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?. Journal of Clinical Oncology 31(25): 3164-3165, 2013